AB-729 is in injected RNAi agent that targets HBsAg.
Not much has changed since the previous update on this phase-1 trial in late 2020 (#msg-159504853). Despite the inclusion of two new dosing cohorts (60mg q8w and 90mg q4w), HBsAg reduction is middling (1.6-1.8 logs at 24w — see slide #9 in the second link above), and it is essentially the same for all three dosing cohorts, which is not a great sign.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.